N-[1-[[(3S,12R,15Z,18R)-3,12-bis(3-amino-3-oxopropyl)-15-ethylidene-21-(1-hydroxyethyl)-18-[(4-hydroxyphenyl)methyl]-7,25-dimethyl-2,5,8,11,14,17,20,23-octaoxo-6-[1-[(3R,4R,5R,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyethyl]-1-oxa-4,7,10,13,16,19,22-heptazacyclopentacos-24-yl]amino]-3-hydroxy-1-oxobutan-2-yl]-2,3-dihydroxytetradecanamide
| Internal ID | 406069d6-3398-445c-b573-441c1f60a7d0 |
| Taxonomy | Organic acids and derivatives > Peptidomimetics > Depsipeptides > Cyclic depsipeptides > Cyclic glycodepsipeptides |
| IUPAC Name | N-[1-[[(3S,12R,15Z,18R)-3,12-bis(3-amino-3-oxopropyl)-15-ethylidene-21-(1-hydroxyethyl)-18-[(4-hydroxyphenyl)methyl]-7,25-dimethyl-2,5,8,11,14,17,20,23-octaoxo-6-[1-[(3R,4R,5R,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyethyl]-1-oxa-4,7,10,13,16,19,22-heptazacyclopentacos-24-yl]amino]-3-hydroxy-1-oxobutan-2-yl]-2,3-dihydroxytetradecanamide |
| SMILES (Canonical) | CCCCCCCCCCCC(C(C(=O)NC(C(C)O)C(=O)NC1C(OC(=O)C(NC(=O)C(N(C(=O)CNC(=O)C(NC(=O)C(=CC)NC(=O)C(NC(=O)C(NC1=O)C(C)O)CC2=CC=C(C=C2)O)CCC(=O)N)C)C(C)OC3C(C(C(C(O3)CO)O)O)O)CCC(=O)N)C)O)O |
| SMILES (Isomeric) | CCCCCCCCCCCC(C(C(=O)NC(C(C)O)C(=O)NC1C(OC(=O)[C@@H](NC(=O)C(N(C(=O)CNC(=O)[C@H](NC(=O)/C(=C/C)/NC(=O)[C@H](NC(=O)C(NC1=O)C(C)O)CC2=CC=C(C=C2)O)CCC(=O)N)C)C(C)OC3[C@@H]([C@@H]([C@H]([C@@H](O3)CO)O)O)O)CCC(=O)N)C)O)O |
| InChI | InChI=1S/C62H99N11O24/c1-8-10-11-12-13-14-15-16-17-18-40(78)49(82)60(93)71-46(31(4)76)57(90)72-47-32(5)95-61(94)38(24-26-43(64)80)68-59(92)48(33(6)96-62-52(85)51(84)50(83)41(29-74)97-62)73(7)44(81)28-65-53(86)37(23-25-42(63)79)67-54(87)36(9-2)66-55(88)39(27-34-19-21-35(77)22-20-34)69-56(89)45(30(3)75)70-58(47)91/h9,19-22,30-33,37-41,45-52,62,74-78,82-85H,8,10-18,23-29H2,1-7H3,(H2,63,79)(H2,64,80)(H,65,86)(H,66,88)(H,67,87)(H,68,92)(H,69,89)(H,70,91)(H,71,93)(H,72,90)/b36-9-/t30?,31?,32?,33?,37-,38+,39-,40?,41+,45?,46?,47?,48?,49?,50+,51-,52-,62?/m1/s1 |
| InChI Key | TZKSEIAJQMPEJX-TZSXGBMXSA-N |
| Popularity | 4 references in papers |
| Molecular Formula | C62H99N11O24 |
| Molecular Weight | 1382.50 g/mol |
| Exact Mass | 1381.68644307 g/mol |
| Topological Polar Surface Area (TPSA) | 566.00 Ų |
| XlogP | -1.20 |
| Atomic LogP (AlogP) | -6.11 |
| H-Bond Acceptor | 24 |
| H-Bond Donor | 19 |
| Rotatable Bonds | 29 |
| There are no found synonyms. |
| Target | Value | Probability (raw) | Probability (%) |
|---|---|---|---|
| Human Intestinal Absorption | - | 0.7416 | 74.16% |
| Caco-2 | - | 0.8616 | 86.16% |
| Blood Brain Barrier | - | 0.9500 | 95.00% |
| Human oral bioavailability | - | 0.7429 | 74.29% |
| Subcellular localzation | Mitochondria | 0.4243 | 42.43% |
| OATP2B1 inhibitior | - | 1.0000 | 100.00% |
| OATP1B1 inhibitior | + | 0.8018 | 80.18% |
| OATP1B3 inhibitior | + | 0.9189 | 91.89% |
| MATE1 inhibitior | - | 0.9600 | 96.00% |
| OCT2 inhibitior | - | 0.9500 | 95.00% |
| BSEP inhibitior | + | 0.9391 | 93.91% |
| P-glycoprotein inhibitior | + | 0.7418 | 74.18% |
| P-glycoprotein substrate | + | 0.8780 | 87.80% |
| CYP3A4 substrate | + | 0.7539 | 75.39% |
| CYP2C9 substrate | - | 1.0000 | 100.00% |
| CYP2D6 substrate | - | 0.8681 | 86.81% |
| CYP3A4 inhibition | + | 0.5066 | 50.66% |
| CYP2C9 inhibition | - | 0.8211 | 82.11% |
| CYP2C19 inhibition | - | 0.9061 | 90.61% |
| CYP2D6 inhibition | - | 0.8200 | 82.00% |
| CYP1A2 inhibition | - | 0.8897 | 88.97% |
| CYP2C8 inhibition | + | 0.8190 | 81.90% |
| CYP inhibitory promiscuity | - | 0.9493 | 94.93% |
| UGT catelyzed | - | 0.6000 | 60.00% |
| Carcinogenicity (binary) | - | 0.9200 | 92.00% |
| Carcinogenicity (trinary) | Non-required | 0.5685 | 56.85% |
| Eye corrosion | - | 0.9859 | 98.59% |
| Eye irritation | - | 0.8959 | 89.59% |
| Skin irritation | - | 0.7614 | 76.14% |
| Skin corrosion | - | 0.9280 | 92.80% |
| Ames mutagenesis | - | 0.6700 | 67.00% |
| Human Ether-a-go-go-Related Gene inhibition | + | 0.6991 | 69.91% |
| Micronuclear | + | 0.8900 | 89.00% |
| Hepatotoxicity | - | 0.6870 | 68.70% |
| skin sensitisation | - | 0.8693 | 86.93% |
| Respiratory toxicity | + | 0.7222 | 72.22% |
| Reproductive toxicity | + | 0.9111 | 91.11% |
| Mitochondrial toxicity | + | 0.9000 | 90.00% |
| Nephrotoxicity | - | 0.6875 | 68.75% |
| Acute Oral Toxicity (c) | III | 0.6485 | 64.85% |
| Estrogen receptor binding | + | 0.5850 | 58.50% |
| Androgen receptor binding | + | 0.7386 | 73.86% |
| Thyroid receptor binding | + | 0.6580 | 65.80% |
| Glucocorticoid receptor binding | + | 0.7988 | 79.88% |
| Aromatase binding | + | 0.7261 | 72.61% |
| PPAR gamma | + | 0.7849 | 78.49% |
| Honey bee toxicity | - | 0.6387 | 63.87% |
| Biodegradation | - | 0.8000 | 80.00% |
| Crustacea aquatic toxicity | + | 0.5226 | 52.26% |
| Fish aquatic toxicity | + | 0.8247 | 82.47% |
Proven Targets:
| CHEMBL ID | UniProt ID | Name | Min activity | Assay type | Source |
|---|---|---|---|---|---|
| No proven targets yet! | |||||
Predicted Targets (via Super-PRED):
| CHEMBL ID | UniProt ID | Name | Probability | Model accuracy |
|---|---|---|---|---|
| CHEMBL4040 | P28482 | MAP kinase ERK2 | 99.99% | 83.82% |
| CHEMBL2581 | P07339 | Cathepsin D | 99.76% | 98.95% |
| CHEMBL3251 | P19838 | Nuclear factor NF-kappa-B p105 subunit | 99.58% | 96.09% |
| CHEMBL5619 | P27695 | DNA-(apurinic or apyrimidinic site) lyase | 99.31% | 91.11% |
| CHEMBL3837 | P07711 | Cathepsin L | 98.43% | 96.61% |
| CHEMBL4203 | Q9HAZ1 | Dual specificity protein kinase CLK4 | 98.02% | 94.45% |
| CHEMBL5103 | Q969S8 | Histone deacetylase 10 | 97.31% | 90.08% |
| CHEMBL2107 | P61073 | C-X-C chemokine receptor type 4 | 97.26% | 93.10% |
| CHEMBL3060 | Q9Y345 | Glycine transporter 2 | 97.03% | 99.17% |
| CHEMBL2955 | O95136 | Sphingosine 1-phosphate receptor Edg-5 | 95.66% | 92.86% |
| CHEMBL5608 | Q16288 | NT-3 growth factor receptor | 95.13% | 95.89% |
| CHEMBL1806 | P11388 | DNA topoisomerase II alpha | 94.16% | 89.00% |
| CHEMBL253 | P34972 | Cannabinoid CB2 receptor | 93.81% | 97.25% |
| CHEMBL2274 | Q9H228 | Sphingosine 1-phosphate receptor Edg-8 | 93.55% | 100.00% |
| CHEMBL255 | P29275 | Adenosine A2b receptor | 92.89% | 98.59% |
| CHEMBL3359 | P21462 | Formyl peptide receptor 1 | 92.72% | 93.56% |
| CHEMBL4227 | P25090 | Lipoxin A4 receptor | 92.68% | 100.00% |
| CHEMBL2563 | Q9UQL6 | Histone deacetylase 5 | 92.12% | 89.67% |
| CHEMBL2514 | O95665 | Neurotensin receptor 2 | 91.73% | 100.00% |
| CHEMBL3137262 | O60341 | LSD1/CoREST complex | 91.59% | 97.09% |
| CHEMBL226 | P30542 | Adenosine A1 receptor | 91.38% | 95.93% |
| CHEMBL5469 | Q14289 | Protein tyrosine kinase 2 beta | 91.31% | 91.03% |
| CHEMBL3108638 | O15164 | Transcription intermediary factor 1-alpha | 90.90% | 95.56% |
| CHEMBL4588 | P22894 | Matrix metalloproteinase 8 | 90.48% | 94.66% |
| CHEMBL3476 | O15111 | Inhibitor of nuclear factor kappa B kinase alpha subunit | 90.25% | 95.83% |
| CHEMBL2069156 | Q14145 | Kelch-like ECH-associated protein 1 | 89.91% | 82.38% |
| CHEMBL5845 | P23415 | Glycine receptor subunit alpha-1 | 89.67% | 90.71% |
| CHEMBL5163 | Q9NY46 | Sodium channel protein type III alpha subunit | 89.40% | 96.90% |
| CHEMBL2094135 | Q96BI3 | Gamma-secretase | 89.18% | 98.05% |
| CHEMBL2345 | P51812 | Ribosomal protein S6 kinase alpha 3 | 89.18% | 95.64% |
| CHEMBL4072 | P07858 | Cathepsin B | 89.05% | 93.67% |
| CHEMBL5852 | Q96P65 | Pyroglutamylated RFamide peptide receptor | 88.81% | 85.00% |
| CHEMBL3038469 | P24941 | CDK2/Cyclin A | 88.72% | 91.38% |
| CHEMBL1907603 | Q05586 | Glutamate NMDA receptor; GRIN1/GRIN2B | 88.54% | 95.89% |
| CHEMBL2996 | Q05655 | Protein kinase C delta | 87.66% | 97.79% |
| CHEMBL3807 | P17706 | T-cell protein-tyrosine phosphatase | 87.13% | 93.00% |
| CHEMBL4478 | Q00975 | Voltage-gated N-type calcium channel alpha-1B subunit | 86.12% | 97.14% |
| CHEMBL3892 | Q99500 | Sphingosine 1-phosphate receptor Edg-3 | 85.35% | 97.29% |
| CHEMBL3130 | O00329 | PI3-kinase p110-delta subunit | 84.59% | 96.47% |
| CHEMBL1907602 | P06493 | Cyclin-dependent kinase 1/cyclin B1 | 84.35% | 91.24% |
| CHEMBL2693 | Q9UIQ6 | Cystinyl aminopeptidase | 84.23% | 97.64% |
| CHEMBL4187 | Q99250 | Sodium channel protein type II alpha subunit | 84.18% | 95.50% |
| CHEMBL1293249 | Q13887 | Kruppel-like factor 5 | 82.99% | 86.33% |
| CHEMBL2111367 | P27986 | PI3-kinase p110-alpha/p85-alpha | 82.84% | 94.33% |
| CHEMBL3392948 | Q9NP59 | Solute carrier family 40 member 1 | 82.50% | 95.00% |
| CHEMBL3891 | P07384 | Calpain 1 | 81.66% | 93.04% |
| CHEMBL2413 | P32246 | C-C chemokine receptor type 1 | 81.32% | 89.50% |
| CHEMBL299 | P17252 | Protein kinase C alpha | 80.97% | 98.03% |
| CHEMBL4769 | O95749 | Geranylgeranyl pyrophosphate synthetase | 80.05% | 92.08% |
Below are displayed all the plants proven (via scientific papers) to contain this
compound!
To see more specific details click the taxa you are interested in.
To see more specific details click the taxa you are interested in.
| There are no matching plants. |
| PubChem | 155802346 |
| LOTUS | LTS0193510 |
| wikiData | Q104203024 |